Cargando…
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provide...
Autores principales: | Donohue, James, Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744553/ https://www.ncbi.nlm.nih.gov/pubmed/31534988 http://dx.doi.org/10.1016/j.dib.2019.104277 |
Ejemplares similares
-
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019) -
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020) -
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017) -
Efficacy and safety of revefenacin for nebulization in patients with
chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA:
subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020) -
Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)